ISRG · Q2 2025 Earnings
CautiousIntuitive Surgical
Reported July 22, 2025
30-second summary
Intuitive printed Q2 revenue of $2.44B (+21% YoY) on da Vinci procedure growth of 17% and 395 system placements, of which 180 were da Vinci 5. The 38.8% non-GAAP operating margin will not hold — management explicitly cautioned this was a favorable mix quarter, and the FY non-GAAP gross-margin guide of 66–67% (vs. 69.1% in 2024) bakes in roughly 100bps of tariff drag plus new-facility depreciation. The story is platform transition (da Vinci 5 broad U.S. launch, Europe/Japan to follow measured pace) against a softer hospital capital backdrop internationally.
Headline numbers
EPS
Q2 FY2025
$2.19
Revenue
Q2 FY2025
$2.44B
+21.4% YoY
Gross margin
Q2 FY2025
66.3%
Operating margin
Q2 FY2025
30.5%
Key financials
Q2 FY2025| Metric | Q2 FY2025 | YoY |
|---|---|---|
| Revenue | $2.44B | +21.4% |
| EPS | $2.19 | — |
| Gross margin | 66.3% | — |
| Operating margin | 30.5% | — |
Guidance
Prior quarter data unavailable — comparison not possible.
Segment KPIs
Q2 FY2025| Segment | Q2 FY2025 | YoY |
|---|---|---|
| Instruments and Accessories | $1.474B | +18.5% |
| Systems | $0.575B | +28.3% |
| Services | $0.391B | +23.2% |
Other KPIs
Q2 FY2025| Segment | Q2 FY2025 |
|---|---|
| da Vinci Procedure Volume Growth | 17% |
| da Vinci Systems Placed | 395 |
| da Vinci 5 Systems Placed | 180 |
| da Vinci Installed Base | 10,488 |
| Ion Procedure Volume Growth | 52% |
| Operating Lease Systems Placed | 193 |
| Non-GAAP Operating Margin | 38.8% |
Management tone
No transcript prepared remarks were available for this brief, so a multi-quarter tone arc cannot be built. The substantive tone signal comes entirely from Q&A. Three observations:
Management actively pushed back on extrapolating Q2 operating margin. Asked by Bank of America's Travis Steed about margin sustainability, the response cited 21% revenue growth, a favorable purchase-lease mix, and OPEX growing only 9% as the drivers and explicitly cautioned that the 39% pro forma operating margin is "not the new normal." The 67.9% non-GAAP gross margin actually sits at or above the FY 66–67% guide, so the cautionary framing is squarely about operating margin — the combination of mix benefit and underspend on OPEX that won't recur — rather than about gross margin per se.
The international rollout posture is deliberately slow. On Wells Fargo's question about ex-U.S. da Vinci 5 pace, management said force feedback instruments won't be cleared in Europe before end of 2026 and explicitly framed the Europe/Japan rollout as "measured" with "infrastructure building required." This is not a company front-running a global launch; it is sequencing capacity, regulatory clearance, and supply (force feedback constrained through Q1 2026) against demand.
The competitive response to remanufactured instruments was framed as innovation and quality, not price. Steed's question on remanufactured instrument competition drew an answer centered on "force feedback, extended use instrumentation, product reliability" and customer-value committees — no mention of pricing actions. This is the right answer strategically but worth tracking: instrument and accessory revenue is the recurring base, and any erosion in INA per procedure would matter more than system placements.
Risks management surfaced:
Q&A highlights
David Roman · Goldman Sachs
Medicaid policy changes and their potential impact on hospital capital spending; how Intuitive is engaging with customers on capital deployment and hospital economics; update on force feedback study impact on INA per procedure.
Management acknowledged it's too early to assess hospital responses to Medicaid coverage changes. Emphasized growing customer analytics engagements where DaVinci can be part of solutions for economic challenges (length of stay reduction, complication reduction). U.S. placements grew 45% with DaVinci 5 broad launch; international markets face government budget constraints. Force feedback supply constrained through Q1 2026; INA per procedure shows early positive momentum from DaVinci 5-specific innovations (force feedback and tube sets), though characterized as smallest contributing factor.
Robert Marcus · JP Morgan
Early evidence on DaVinci 5 productivity improvements versus XI; implications for upgrade cycle and revenue generation; share repurchase rationale and capital allocation strategy.
Management stated productivity data building phase; average system utilization on DaVinci 5 recently surpassed XI, though work remains to demonstrate robust evidence. Internal tracking shows savings exceeding 20% on individual cases. Goal is enabling hospital teams to add another case per day. Capital allocation priorities: organic investment in R&D and CapEx, tuck-in acquisitions, opportunistic shareholder returns. Q2 repurchases reflected recognition of trade environment volatility.
Larry Bigelson · Wells Fargo
System placement outlook outside U.S. following DaVinci 5 CE mark and Japan approval; expected rate of trade-in acceleration post-broad launch and financial implications.
Management stated measured DaVinci 5 rollout planned in Europe/Japan with infrastructure building required; force feedback instruments not expected cleared in Europe before end of 2025, which may cause some customers to wait. Early adopters expected in both regions. Trade-ins expected to increase progressively over multiple years as customers evaluate DaVinci 5 from clinical, efficiency, and financial perspectives. No specific pricing implications disclosed.
Travis Steed · Bank of America Securities
Margin expansion drivers in Q2 despite tariff headwinds; sustainability of current margin levels; remanufactured instruments competitive response strategy.
Q2 margin strength driven by 21% revenue growth, purchase-lease mix benefit, and OPEX growing only 9%, allowing leverage through P&L. Management cautioned Q2 results not representative of 'new normal' due to purchase mix variability and OPEX growth timing. On remanufactured instruments: emphasized customer value committees evaluate safety, reliability, performance, supply continuity, and support. Intuitive's competitive response is continued innovation (force feedback, extended use instrumentation, product reliability) and cost reduction while maintaining service quality.
Rick Weiss · Stifel
DaVinci 5 expansion into new venues (ASCs, endovascular, etc.); DaVinci 5 product roadmap for features, capabilities, and software; implications for adoption, utilization, and ASP/margins.
Management sees ASC opportunity enabled by trade-ins (moving XI/X to ASCs while placing DaVinci 5 in hospitals). Emphasized robust platform roadmap analogous to XI's decade-long evolution. 3D model integration highlighted as near-term capability enabled by increased compute power. Most upcoming features expected free to customers to drive adoption and feature utilization; some digital capabilities may have pricing. Features expected to enhance surgeon experience and system capability without direct charge.
What to watch into next quarter
Non-GAAP gross margin trajectory toward the 66–67% FY band — Q2 non-GAAP gross margin of 67.9% sits above the FY guide; watch whether tariff drag, new-facility depreciation, and DV5 mix push it into or below the range in Q3.
da Vinci 5 share of systems placed — 180 of 395 (~46%) in Q2; watch whether this share rises sequentially as U.S. broad launch matures and whether Europe/Japan begin contributing meaningfully (management guidance: force feedback clearance in Europe not expected before end of 2026).
Trade-in count — 83 in Q2 vs. 21 a year ago; watch whether the multi-year trajectory management described shows continued acceleration above 100/quarter, which would validate the upgrade-cycle thesis.
Procedure growth at the upper end vs. lower end of 15.5–17% FY guide — Q2 ran +17%, the top of the range. A Q3 print below 16% would suggest the FY guide was front-loaded.
INA per procedure direction — management said force feedback and tube sets are early positive contributors; this is the recurring revenue base and matters more than any single quarter of system placements. Watch for explicit disclosure of INA per procedure direction next quarter.
International system placements, specifically Japan — down 26 units YoY in Q2; watch whether the trough is in or whether government budget pressure deepens.
Sources
- Intuitive Surgical Q2 2025 earnings press release, filed with SEC (https://www.sec.gov/Archives/edgar/data/1035267/000103526725000183/q225ex-991earningsrelease.htm)
- Intuitive Surgical Q2 2025 earnings call Q&A (analyst exchanges with Goldman Sachs, JP Morgan, Wells Fargo, Bank of America)
Get the next brief, free.
We publish analyst-grade earnings briefs the same day or morning after every call — headline numbers, segment KPIs, Q&A highlights, and tone analysis. Free during beta.
This is not investment advice.